In the SELECT trial, a single-arm study that enrolled a total of 100 patients with resected stage IA-IIIA EGFR mutant + NSCLC, the use of adjuvant erlotinib for 2 years led to a 5-year DFS of 56% among the study participants and a 5-year OS of 86% [80]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.